{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:10:14Z","timestamp":1784675414399,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To ascertain the frequency of adrenal insufficiency in patients with GCA treated using the Norwich prednisolone regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients diagnosed with GCA between 1 January 2012 and 31 May 2022 were included. All patients were treated with the Norwich prednisolone regimen, educated about the benefits and risks of long-term prednisolone use and followed up in dedicated vasculitis clinics. When patients contacted the advice line to report being unwell, tests for adrenal function were performed after ruling out relapsing vasculitis or polymyalgia rheumatica. A 9\u2009a.m. serum cortisol was used, providing the daily dose of prednisolone was \u22645\u2009mg, as a gateway to dynamic testing with full-form adrenocorticotrophic hormone (ACTH) stimulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 353 consecutive patients with GCA were included. During the prescribed glucocorticoid tapering regimen, 76\/353 had a 9\u2009a.m. serum cortisol check after ruling out relapsing disease. Of these, 34\/76 had a serum cortisol &amp;gt;350\u2009nmol\/l (our laboratory cut-off for adequacy of adrenal reserve); 7\/76 had a serum cortisol &amp;lt;100\u2009nmol\/l, indicative of insufficient adrenal function and 35\/76 had a cortisol level of 100\u2013350\u2009nmol\/l. Of the 35 patients who went on to have a standard-dose ACTH stimulation test, 27\/35 had an adequate result (i.e. &amp;gt;450\u2009nmol\/l at 30\u2009min) and 8\/35 had an inadequate result. A total of 15\/353 patients required long-term steroids because of adrenal insufficiency and 11\/15 patients with adrenal insufficiency were female. The median (IQR) cumulative prednisolone dose at the time of testing was 11.53\u2009grams (7.74) and the median (IQR) duration of prednisolone was 121\u2009weeks (97).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is the largest study studying the frequency of adrenal insufficiency in patients with GCA treated using the Norwich prednisolone regimen. Adrenal insufficiency requiring long-term steroid replacement therapy is uncommon. Sequential testing using 9\u2009a.m. serum cortisol levels as a gateway to rationalizing the necessity for dynamic testing with standard-dose ACTH stimulation testing is an efficient strategy for this cohort of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkaf050","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:25:58Z","timestamp":1745853958000},"source":"Crossref","is-referenced-by-count":1,"title":["Adrenal insufficiency in giant cell arteritis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-0604","authenticated-orcid":false,"given":"Georgina","family":"Ducker","sequence":"first","affiliation":[{"name":"Vasculitis Unit, Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust , Norwich,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-9579","authenticated-orcid":false,"given":"Ketan","family":"Dhatariya","sequence":"additional","affiliation":[{"name":"Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospitals NHS Foundation Trust , Norwich,","place":["UK"]},{"name":"Norwich Medical School, University of East Anglia , Norwich,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-6667","authenticated-orcid":false,"given":"Chetan B","family":"Mukhtyar","sequence":"additional","affiliation":[{"name":"Vasculitis Unit, Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust , Norwich,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2025060916564492100_rkaf050-B1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/ard-2023-224191","article-title":"Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020","volume":"82","author":"Mukhtyar","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025060916564492100_rkaf050-B2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.1957.02970450023007","article-title":"Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy","volume":"163","author":"Birkhead","year":"1957","journal-title":"J Am Med Assoc"},{"key":"2025060916564492100_rkaf050-B3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025060916564492100_rkaf050-B4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025060916564492100_rkaf050-B5","doi-asserted-by":"crossref","first-page":"rkz001","DOI":"10.1093\/rap\/rkz001","article-title":"Development of an evidence-based regimen of prednisolone to treat giant cell arteritis\u2014the Norwich regimen","volume":"3","author":"Mukhtyar","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"2025060916564492100_rkaf050-B6","doi-asserted-by":"crossref","first-page":"G25","DOI":"10.1093\/ejendo\/lvae029","article-title":"European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"190","author":"Beuschlein","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 2","key":"2025060916564492100_rkaf050-B7","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/kex459","article-title":"Prevention of glucocorticoid morbidity in giant cell arteritis","volume":"57","author":"Buttgereit","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025060916564492100_rkaf050-B8","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2013-1394","article-title":"Pituitary-adrenal function after prolonged glucocorticoid therapy for systemic inflammatory disorders: an observational study","volume":"98","author":"Sacre","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060916564492100_rkaf050-B9","doi-asserted-by":"crossref","first-page":"e68713","DOI":"10.1371\/journal.pone.0068713","article-title":"Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study","volume":"8","author":"Jamilloux","year":"2013","journal-title":"PLoS One"},{"key":"2025060916564492100_rkaf050-B10","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1093\/rheumatology\/keaa239","article-title":"Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach","volume":"59","author":"Borresen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025060916564492100_rkaf050-B11","first-page":"655","article-title":"Survey of patient knowledge and awareness of \u201csick day rules\u201d in rheumatology patients on long term glucocorticoid therapy","volume":"115","author":"Courtney","year":"2022","journal-title":"Ir Med J"},{"key":"2025060916564492100_rkaf050-B12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0140-6736(65)91526-6","article-title":"A rapid test of adrenocortical function","volume":"1","author":"Wood","year":"1965","journal-title":"Lancet"},{"key":"2025060916564492100_rkaf050-B13","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.7861\/clinmed.2021-0126","article-title":"Improving the quality of care for people with giant cell arteritis","volume":"21","author":"Mukhtyar","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"2025060916564492100_rkaf050-B14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/rheumatology\/keae493","article-title":"Ultrasonography led multimodal diagnostic pathway for giant cell arteritis","volume":"64","author":"Mukhtyar","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025060916564492100_rkaf050-B15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/rheumatology\/keu483","article-title":"Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency","volume":"54","author":"Unizony","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkaf050\/63021751\/rkaf050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/2\/rkaf050\/63021751\/rkaf050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/2\/rkaf050\/63021751\/rkaf050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:56:57Z","timestamp":1749502617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaf050\/8121163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaf050","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rkaf050"}}